Diabetics Doing Things
Episode 335 · Sep 12, 2025 · 19 min

Euglycemic DKA & Other Hidden Dangers with Dr. Eden Miller

Eden Miller
0:00 / 19:00
Episode summary

Dr. Eden Miller returns for part two of a three-part DKA series to explain euglycemic DKA, a state where ketones build up even though blood sugar looks normal. She walks through how low-carb or carnivore eating, SGLT2 inhibitors, and GLP-1 medications can each lower insulin levels enough to trigger ketosis without high glucose. She also covers pregnancy and prolonged fasting as risk periods, and explains why symptoms like nausea, vomiting, and confusion matter as much as glucose numbers. The episode closes with practical steps: check ketones regardless of glucose, and build a plan with your clinician for testing and when to call for help.

Key takeaways
  • Dr. Miller says euglycemic DKA, which she calls 'lower threshold DKA,' can happen with blood sugar under 250, not just when glucose is high.
  • She says SGLT2 inhibitors raise DKA risk because they lower blood sugar through the kidneys, which can mask the need for insulin and lead people to under-dose.
  • She says GLP-1 medications don't directly cause DKA but can facilitate it if someone cuts back their insulin too much while on the drug.
  • She says pregnancy and prolonged fasting both raise DKA risk because insulin needs change in ways that are hard to predict.
  • She recommends checking ketones based on symptoms like nausea or confusion even when glucose looks normal, and having a clear plan with your clinician for when to test and when to call.
Chapters
  • Introduction to Euglycemic DKA
  • Understanding Euglycemic DKA
  • Impact of Medications on DKA
  • Symptoms and Confirmation of DKA
  • The Importance of Regular Ketone Checks
  • Exploring GLP-1 Medications
  • Other Causes of DKA
  • Preventing Euglycemic DKA
Show notes

Disclaimer: The views expressed in this video should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations and circumstances may vary.

Sponsored by Abbott

Summary

In this episode, Dr. Eden Miller discusses the concept of Euglycemic DKA, a condition that can occur even when blood sugar levels are normal. The conversation covers the importance of understanding the symptoms, the role of medications like SGLT2 and GLP1 in increasing the risk of DKA, and the necessity of regular ketone checks. Dr. Miller emphasizes the need for education and empowerment in managing diabetes, especially in unique situations like pregnancy and prolonged fasting. The episode concludes with strategies for preventing Euglycemic DKA.

Chapters

00:00 Introduction to Euglycemic DKA

02:00 Understanding Euglycemic DKA

04:08 Impact of Medications on DKA

07:10 Symptoms and Confirmation of DKA

09:20 The Importance of Regular Ketone Checks

11:07 Exploring GLP-1 Medications

12:30 Other Causes of DKA

16:22 Preventing Euglycemic DKA

Resources:

https://diabetesandobesity-care.com/

https://www.linkedin.com/in/eden-miller-b02a5a178 

Questions this episode answers

What is euglycemic DKA?

Dr. Eden Miller explains it as diabetic ketoacidosis that happens with blood sugar in or near normal range, often under 250, rather than the high glucose levels typically associated with DKA. She prefers calling it 'lower threshold DKA.'

Can SGLT2 inhibitors cause DKA?

Dr. Miller says SGLT2 inhibitors are more strongly linked to DKA risk than GLP-1s because they lower blood sugar by dumping glucose through the kidneys, which can hide the need for insulin and lead to under-dosing.

Do GLP-1 medications cause DKA?

According to Dr. Miller, GLP-1s don't directly cause DKA. She describes them as facilitators, since they can lower a person's insulin requirement and create risk if insulin doses aren't adjusted properly.

How can someone prevent euglycemic DKA?

Dr. Miller recommends checking ketones based on symptoms rather than glucose alone, and talking with your clinician in advance about when to test, when to call, and what to do during pregnancy, fasting, or low-carb eating.

Full transcript Searchable, with timestamps

Rob Howe: Hello, listeners. What you are about to hear is a series that I've been working on for quite some time, and I've taken great care in every aspect of it because it's centered around a very serious topic, diabetic ketoacidosis, or DKA. But we know that by openly discussing serious topics, we can take some of the fear away from them, learn about them, and hopefully improve the way that we deal with them. Name it to tame it. So this is a five-part series where we discuss diabetic ketoacidosis. It is sponsored by Abbott. The views expressed should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations, and circumstances may vary. The series is in our podcast feed as well as on YouTube, Instagram, and TikTok. I hope you find it informative, entertaining, and I hope it helps you understand a little bit more about DKA, its causes, and what you can do to make sure you're ready in a DKA situation. Enjoy. Welcome back to another episode of Diabetics Doing Things. We are telling the amazing stories of people with diabetes from all across the world. This is part two of a three-part series with Dr. Eden Miller as part of our DKA Awareness series here. Dr. Miller, welcome back to the show. Today, we are talking about something that I lived with diabetes for more than 10 years before I heard anything about. And when I got into the diabetes online community, it was something that popped up pretty frequently. And that is euglycemic DKA and other hidden dangers explained. So let's talk a little bit about that. Welcome back to the show.

Eden Miller: Yeah, thanks so much. Yeah, euglycemic DKA. Okay, I'm gonna go spicy on you right away. You know, euglycemic DKA was this terminology that came out probably about 10 years or so ago. There are a lot of scenarios that we'll definitely cover, But really, I like to call it lower threshold DKA. I don't know why. I just do. The reason is, is because the terminology of euglycemia implies normal glycemia. And we're actually defining normal glycemia right now. We don't even have that defined. We have time and range. I'm not going to go against that, you know, 70 to 180. But I call it lower threshold DKA because you and I were kind of trained or if we look at the standards of care for detecting or looking for ketones because we're going to learn to check even if your glucose is lower than you would think would be at risk, but traditionally was like 250 or 300. So what I'm going to be talking about is this euglycemic slash lower threshold DKA to say, guess what? You can have ketosis. You're going to have early DKA or even DKA when your blood sugar is less than 250, which that means I don't want glucose to be the only

Rob Howe: determiner for you to check it out. Right. So let's do a little scenario. I think this is a great way for us on the podcast as two podcasters. I'm very grateful for your podcast experience as well as your lived experience and your clinical experience with diabetes. So I want you to react to this statement. My glucose is in normal range or I mean, let's say between 70 and 180 as we're talking about with time and range. But I think I'm in DKA. Yeah, it's because the glucose does

Eden Miller: not necessarily follow the ketones. Yes, I'm not going to disagree with you or tell our listeners out there that high glucose doesn't correlate with a risk of DKA, but it really is a relative insulin deficiency given the current scenario. Okay, here's a great example. If you were to quit eating carb altogether, you were going total primal, you were going total caveman, eating only protein. And as a result, you reverse titrated your insulin, right? You pulled it back because you were like, I'm not going to go low. I'm not eating carbs. I'm doing this. And let's say you dipped below your metabolic threshold. How do we know our metabolic threshold? We don't have a way to calculate. We don't have a way to do it. I can tell you if moderate to high ketones show up, not nutritional ketosis, because we talked about that in episode one, when we talk about how you're going to burn a little fat, right? But imagine if you, because of your diet, then started pulling back the insulin to the point where you didn't even cover your breathing and your heartbeat, you could potentially start spilling ketones even though you didn't have an elevated glucose.

Rob Howe: That's just one particular scenario. And that's a situation that we talked about again in episode one, like when your insulin needs change dramatically, right? So, and like you said, we have no way of knowing what a person's individual metabolic threshold is. And so that lack of insulin may not be enough to, you know, provide us with the range that we need, even though our glucose isn't reflecting as out of range. So you mentioned the diet aspect and going full primal, all protein, whatever that looks like. But also there are multiple medications now that people who are on insulin living with diabetes are taking, SGLT2 inhibitors and GLP-1s. So how do those factor into increased cases of euglycemic DKA in patients that are on insulin?

Eden Miller: So let's talk about that in two little veins because I think it's important. Right now, SGLT2s and GLP-1s are not approved in the U.S. for type 1. However, they're really routinely used for those in type 2 diabetes. So when we look at the two drugs together, I would say the SGLT2s are definitely more prone for developing what we call this lower threshold DKA. GLP-1s, not so much. I will get to the GLP-1s in a little bit. But still, the same scenario exists for, let's say, those individuals with type 1 diabetes, insulin deficient or absence, that are on those meds. Now, why am I talking about it? Because I'm setting a foundation, not that I have a magic crystal ball or have any vote, but, you know, we are looking as thought leaders forward in the future to say, hey, can we safely use these in type 1s? Are there some benefits? I'm not going to go into that today, but let's just talk about the risks in the association because of the pharmacokinetics and dynamics, the effects of the med. So SGLT2s, let's tackle that one at first. So SGLT2s are what we call glucose eliminators. They're pancreatic independent. You could have a non-intact pancreas. You and I still have kidneys. And we dump sugar in the urine because we lower the threshold, sucking back the glucose in the kidney. It was really amazing because it actually is not detrimental to the kidney. It's actually helpful. But as we dump sugar into the kidney, it goes out in the urine. And so we have what's called a hidden glucose. You know what I mean? Your sugar is lower. And what's the impetus for insulin administration with you and I, other than meals? High sugar, right? So if our insulin is lower and we happen to be on that drug, whether we're a type 2 or using it outside of the approval as a type 1, we sometimes don't take enough insulin because we're like, our sugar's good. So we get into a scenario of relative insulin deficiency, right? It's just a different way to get there. Now, I'll add one more thing, which not even a lot of clinicians know. When you take an SGLT2, we actually burn a little fat. That's not a bad thing. It's because the heart loves ketones. It actually loves ketones. That's a whole other podcast of those ketone bodies, how they suck them up and they make them happy. But ketones can be helpful in some scenarios. So imagine a drug that eliminates glucose, lowers your glucose threshold or your insulin threshold, and you are producing a little bit of ketones. So you see how it can be a perfect scenario, plus a little dehydration, you're not eating. Let's say you're a type 2 variant that doesn't make enough insulin. You go on an SGLT2, you don't even realize it, you're pulling back your insulin, now you have ketosis. So you see how the interplay is with that particular kind of med.

Rob Howe: For sure. I mean, it kind of puts you in a perfect scenario, like you said, to slip easily into DKA if a couple other things change, right? So I want to talk about how do you confirm this if you have euglycemic DKA, even if you don't have or you're mild to moderate hyperglycemia, only slightly out of range. But what other factors? Do the signs of elevated ketones and DKA that we talked about in episode one, nausea, vomiting, severe thirst, maybe confusion, do those also show up in euglycemic DKA?

Eden Miller: Absolutely. And I don't want our listeners to be scared like DK is going to creep up on them and they don't even know it next thing they know it's going to punch them, right? Rather, we still see the symptoms related to the ketone body formation that we talked about in episode one, where we see that beta-hydroxybutyrate, the acetoacetate, where it rises, they're big acid proponents, they change the pH of the blood, they cause acidosis. that direct acidosis causes nausea, causes vomiting, causes confusion in the end state, dehydration, increased urination kind of thing, trying to dilute it, right? And so that's why I want to just let our listeners know, of course, when your glucose is up, you're going to check. But how about you check for ketones, even if you don't feel well, regardless of what your glucose is. Or remember we talked about in episode one, scenarios. Let's say you're in a scenario where you might have that lower threshold or euglycemic DKA, just check it out. Like, just see what it is. So fortunately, the symptoms are the same because the same biochemistry is going on, the same increase in the ketones, and it's also the same risk or type of DKA. You know what I mean? Like that. So we want to be mindful of it because we can do a lot to identify and prevent because there's so much lead in until it's serious. So let's get on board with the lead in.

Rob Howe: Well, it sounds like normalizing regular ketone checks, whether it's through the blood monitor or through the test strips and the urine strips, is something that we should just continue to talk about more openly. It's a really quick checklist of making sure that you're not in danger of DKA, no matter what your glucose readings are.

Eden Miller: Exactly. Like how long does it take to check it out? And isn't that great that you dodge the bullet of a hospital evaluation or that, or you talk to your clinician? Such a small investment in time for a great return.

Rob Howe: So we talked about SGLT2. You mentioned we'd come back to GLP-1. So I want to give you a chance to explain that before we kind of move forward with the rest of the discussion on EDKA.

Eden Miller: So GLP-1s are another class of medications we particularly use in type 2 diabetes. Again, we're looking forward, not approved right now. But there are a lot of benefits that GLP-1s can provide for us with diabetes that are beyond just insulin. So we're always looking to have that complete health picture. So GLP-1s are biologics. They deal with the glucose you make and the glucose you take, and they help with release of insulin in the pancreas, but you and I don't make insulin. But yet we still make glucagon, and so it's the counter-regulatory hormone. And so in certain cases, I would say a case that comes to mind for me are those of a kind of advanced stage who develop what we call a kind of type 1. They're called LADAs, latent autoimmune diabetes in adults. They're kind of a slow-progressing type 1. They generally have one antibody. You know, they go slow. They slowly kind of require insulin over time. But imagine you give a GLP-1 to these people, which is not contraindicated by any means, and they still see benefit. But imagine they stop using their insulin, right? Because they're inhibiting their glucagon, their, you know. And so again, you've created another scenario where your metabolic needs or your insulin deficiency is below what you need in order to survive. And so you've done that through another therapy or another drug. Now, I will tell you, historically, GLP-1s are not highly implicated in DKA. They're only going to be associated when the insulin level goes down. So I want our listeners to understand that these drugs don't cause DKA. They facilitate DKA because what are we doing? We're adjusting the insulin levels or we're adjusting the metabolic response. OK, so they're facilitators, not direct causers. And later, as we learn more about DKA, some people are more DKA prone than others. And so we're going to have to tackle that if we ever do get these therapies approved for those with type 1.

Rob Howe: I like the idea or like the concept of framing things as facilitators, because as we talked about in episode one, most of the situations where you're at an increased risk of DKA are just around changes. So whether that's insulin needs or whether it's schedules or stress or lack of sleep. And when we talk about these other facilitators, we've mentioned SGLT2, we talked about GLP-1 creating an environment where DKA is maybe more likely, even though it's not a direct cause. We talked about the primal keto type diet that could also create an environment where that's more likely. What about these other causes like pregnancy? I have down as one. And then also just prolonged fasting, someone who's on maybe a multiple day fast and gets below their metabolic threshold for insulin. Exactly. What should we watch out for in those two scenarios?

Eden Miller: So pregnancy is one of those things that if we can just grade education top down, yes, type 1 diabetes has a higher rate of decay in pregnancy. fortunately our OBGYN brethren are so aware of that, utilizing those things for detecting, making sure they have a low threshold with that. It also can creep on those up with type 2 diabetes. Again, do we have a way to measure how much insulin you're producing? No. Do we have a way to measure how much you need or your gas mileage? That's why I call this your gas mileage, right? Imagine you're going uphill and your gas mileage goes down, then you're going downhill and your gas mileage goes up. Well, it happens every day with us, even throughout the different scenarios. So pregnancy that's that educational piece, making sure you're having conversation with your clinician, regardless of what type of diabetes you have, but having an even lower threshold. Why? Because you are supporting and growing another life and you can become insulin deficient. Not only that, you're in a building mode. You're in a breakdown mode. You are, that nutrition is going to that baby. And so you are taking all your own nutrition and prioritizing that kiddo. So that's that potential time. Then that other is prolonged fasting. And that's going to go directly to what almost like a ketogenic diet, because if you have a prolonged fasting, you're really not taking any food. You're kind of giving the message to your body, you're on your own, make your own glucose. And so the body's going to go to glycogen, which we all know that's the muscle carbohydrate. I call it the diabetes pantry. We go open the pantry door, we eat from there. But then when that's empty, where do you go next? Well, we actually go to protein first. We break down the protein in our body first and then we go to fat. And so imagine how does your fasting and my fasting affect it? We're going to learn so much about ketosis prone states. And you know how like you have those foods that raise your blood sugar, but maybe they don't raise mine like pizza is fine, but granola hates me, you know, kind of thing. We're going to see individualized ketosis prone states too, where maybe you fast for a day and you start spilling ketones, or I fast for a day and it doesn't happen. And so that's why we're setting that foundation of checking for the future to say, we're going to be able to individualize this, which is great, just like glucose, just like food. And so it's becoming aware of your individual scenarios where you're going to check it out and those situations that you're going to go, you know what? I got to check ketones, even if your blood sugar is what we don't consider a high level to do it. So it's

Rob Howe: kind of like, if in doubt, check it out. It's so fascinating to me how diabetes varies based on person so much. And, you know, what works for one person or a protocol that works great for one person may not even come close to another. Or you brought up pizza is fine for you, not as fine for me. I've got to have a full checklist and people on board a full control center to help me navigate that most of the time. So I think it's just, it's really interesting as I continue to learn more about the scenarios and situations that cause certain things with diabetes and dealing and talking with other people in the community and having that sort of shared experience of, well, what did you do in this situation? And it'd be totally different. And we get to the same outcome from my own experience. So really, really interesting to learn about. I think as we kind of close the discussion on euglycemic DKA, obviously we've talked about the common cause We talked about what to look out for and the scenarios that could cause it. But what can we do to help prevent euglycemic DKA? Obviously, like you said, test it quickly just to put it out of sight, out of mind, to make sure that we're not dropping ketones. But how can we prevent euglycemic DKA?

Eden Miller: I think prevention is education. I think our listeners, if they could take away one thing from this episode, is that the sugar doesn't always have to be high. I think right there, knowing that, you're like, okay, I didn't know that. Number two is that the symptoms do matter and you have to check out are the symptoms that are having are the signs, which are not always specific. Maybe you ate the bad Chinese food, but maybe you are actually producing ketones. That we're going to check those out. Then what I want you to do is create your own diabetes story where you say to your clinician, again, I welcome this as a provider. And I hope that our listeners have that experience as well, that they have that communication with their clinician. hey, by the way, I need ketone strips. And if somebody's like, well, you don't, just say, I feel more comfortable with that type of thing, or I need this kind of thing. It's your disease. Empower yourself if you don't always have somebody empowering you as well. And then have that conversation with your healthcare provider. There are a lot of different providers, right? We have CDEs, we have PharmD's, we have the clinicians that are prescribers. So have the conversation to say, hey, I've noticed this in me. This is what I do. Do you have any feedback? Like, what should I do? You know, should I have a low threshold for testing? Sure. When do you want me to call you? When is, what's my DKA plan? Number three, what do you want me to do? What's my troubleshooting? Like, what am I going to troubleshoot with? Am I going to check my site? Am I going to do this? When do you want me to wake you up in the middle of the night? When do you want me to go in? And then what are some simple things you can do to mitigate it? because yes, I do not want anybody to think that I'm actually having you manage at home because, but there are scenarios or early stages where if you catch it early and you reverse or attend to the facilitator of the DKA, that you can maybe pause it or reverse it or derail it. At least you do that before you call your clinician, while you're calling your clinician, okay? And a lot of it is just simple hydration and attending and doing all those things Because you know what? Yes, our clinician is like our navigator, but we're still rowing our diabetes boat. Right. And we can do some things to empower it.

Rob Howe: Yeah, I love the maritime analogy or like you're the pilot, but you're radioing the tower, you know, and you're getting guidance from somebody who has more perspective. So excellent information and advice. Dr. Miller, thank you. This was episode two of our series on DKA and expanding DKA awareness. So be sure to check out the rest of the episodes that are in the feed. And Dr. Miller, we'll see you for episode three.

About Eden

Dr. Eden Miller is a physician focused on diabetes and obesity care and a co-founder of Diabetes and Obesity Care. She also hosts her own podcast and works with patients and clinicians on diabetes education and management.

One email a week.

New episodes, events, and what the community is talking about.